Hypertension and chronic kidney disease in Asian populations
- PMID: 33538081
- PMCID: PMC8029545
- DOI: 10.1111/jch.14188
Hypertension and chronic kidney disease in Asian populations
Abstract
The countries of Asia are home to multiple ethnicities. There are ethnic differences in diet, culture, and attitudes towards health screening, access to care, and treatment of chronic diseases. Chronic kidney disease (CKD) and end-stage kidney disease (ESKD) have rising incidence and prevalence due to increased affliction with non-communicable diseases of diabetes and hypertension. To prevent the expensive complications of ESKD, one of the most important risk factors to control is hypertension in patients with CKD. We performed a narrative review on the prevalence of CKD in patients with hypertension, the prevalence and control of hypertension in patients with CKD, and the dietary sodium intake in CKD populations.
Keywords: Asian; blood pressure; chronic kidney disease; hypertension; kidney disease; multi-ethnicity; sodium.
© 2021 The Authors. The Journal of Clinical Hypertension published by Wiley Periodicals LLC.
Conflict of interest statement
YC Chia has received honorarium and sponsorship at attend conferences and seminars from Boeringher‐Ingelheim, Pfizer, Omron, Servier and Xepa‐Sol and an investigator‐initiated research grant from Pfizer. S Siddique has received honoraria from Bayer, Novartis, Pfizer, ICI, and Servier; and travel, accommodation, and conference registration support from Hilton Pharma, Atco Pharmaceutical, Highnoon Laboratories, Horizon Pharma and ICI. CH Chen reports personal fees from Novartis, Sanofi, Daiichi Sankyo, SERVIER, Bayer, and Boehringer Ingelheim Pharmaceuticals, Inc HM Cheng received speakers honorarium and sponsorship to attend conferences and CME seminars from Eli Lilly and AstraZeneca; Pfizer Inc; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc; Daiichi Sankyo, Novartis Pharmaceuticals, Inc; SERVIER; Co., Pharmaceuticals Corporation; Sanofi; TAKEDA Pharmaceuticals International and served as an advisor or consultant for ApoDx Technology, Inc The other authors have no conflict of interest to declare.
Similar articles
-
CKD in China: Evolving Spectrum and Public Health Implications.Am J Kidney Dis. 2020 Aug;76(2):258-264. doi: 10.1053/j.ajkd.2019.05.032. Epub 2019 Sep 3. Am J Kidney Dis. 2020. PMID: 31492486 Review.
-
Management of Hypertension in Patients with Chronic Kidney Disease in Asia.Curr Hypertens Rev. 2016;12(3):181-185. doi: 10.2174/1573402113666161122114854. Curr Hypertens Rev. 2016. PMID: 27875953 Review.
-
Risk of Progression of Nonalbuminuric CKD to End-Stage Kidney Disease in People With Diabetes: The CRIC (Chronic Renal Insufficiency Cohort) Study.Am J Kidney Dis. 2018 Nov;72(5):653-661. doi: 10.1053/j.ajkd.2018.02.364. Epub 2018 May 18. Am J Kidney Dis. 2018. PMID: 29784612
-
Factors Associated with Chronic Kidney Disease and Their Clinical Utility in Primary Care Clinics in a Multi-Ethnic Southeast Asian Population.Nephron. 2018;138(3):202-213. doi: 10.1159/000485110. Epub 2017 Dec 15. Nephron. 2018. PMID: 29253844
-
Progression to end-stage kidney disease in Japanese children with chronic kidney disease: results of a nationwide prospective cohort study.Nephrol Dial Transplant. 2014 Apr;29(4):878-84. doi: 10.1093/ndt/gfu012. Epub 2014 Feb 9. Nephrol Dial Transplant. 2014. PMID: 24516225
Cited by
-
Prevalence and Predictors of Renal Disease in a National Representative Sample of the Romanian Adult Population: Data from the SEPHAR IV Survey.Diagnostics (Basel). 2022 Dec 16;12(12):3199. doi: 10.3390/diagnostics12123199. Diagnostics (Basel). 2022. PMID: 36553206 Free PMC article.
-
Metabolomics of Artichoke Bud Extract in Spontaneously Hypertensive Rats.ACS Omega. 2021 Jul 12;6(29):18610-18622. doi: 10.1021/acsomega.1c01135. eCollection 2021 Jul 27. ACS Omega. 2021. PMID: 34337201 Free PMC article.
-
Data analytics approach for short- and long-term mortality prediction following acute non-ST-elevation myocardial infarction (NSTEMI) and Unstable Angina (UA) in Asians.PLoS One. 2024 Feb 15;19(2):e0298036. doi: 10.1371/journal.pone.0298036. eCollection 2024. PLoS One. 2024. PMID: 38358964 Free PMC article.
-
The burden of chronic kidney disease in Asia region: a review of the evidence, current challenges, and future directions.Kidney Res Clin Pract. 2025 May;44(3):411-433. doi: 10.23876/j.krcp.23.194. Epub 2024 Sep 9. Kidney Res Clin Pract. 2025. PMID: 39384350 Free PMC article.
-
Age and estimated glomerular filtration rate in Chinese older adults: a cohort study from 2014 to 2020.Front Public Health. 2024 Jun 25;12:1392903. doi: 10.3389/fpubh.2024.1392903. eCollection 2024. Front Public Health. 2024. PMID: 38983263 Free PMC article.
References
-
- Kidney Disease Outcomes Quality Initiative (K/DOQI) . K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43(5 Suppl 1):S1‐S290. - PubMed
-
- KDOQI . KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2007;49(2 Suppl 2):S12‐S154. - PubMed
-
- Jinam TA, Kanzawa‐Kiriyama H, Inoue I, Tokunaga K, Omoto K, Saitou N. Unique characteristics of the Ainu population in Northern Japan. J Hum Genet. 2015;60(10):565‐571. - PubMed
-
- Subramanian S, Teo BW, Toh QC, et al. Spot urine tests in predicting 24‐hour urine sodium excretion in Asian patients. J Ren Nutr. 2013;23(6):450‐455. - PubMed
-
- Wu Y, Huxley R, Li L, et al. Prevalence, awareness, treatment, and control of hypertension in China: data from the China national nutrition and health survey 2002. Circulation. 2008;118(25):2679‐2686. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical